
ashm RESU DECISION MAKING IN HEPATITIS C

1 When To Test

٠

٠

2 Test/s, Results and Actions



This resource was originally developed by ASHM. It has been adapted for Egypt by ASHM and the International Network on Health and Hepatitis in Substance Users (INHSU) in collaboration with local partners.

*If high level suspicion also consider requesting reflexive HCV RNA

⊖HC

ashm THEO DECISION MAKING IN HEPATITIS C

()\/ ⊖→ H(

3 Pre-Treatment Assessment

Baseline screening after positive HCV PCR

- □ Complete Blood Count (CBC)
- □ Urea, electrolytes, creatinine
- AST, ALT, GGT, ALP, Tbil, Dbil, INR, Alb

Assess liver fibrosis: cirrhotic status

- □ Signs of chronic liver disease (spider naevi, palmar erythema, jaundice, encephalopathy, hepatomegaly, splenomegaly, ascites, peripheral oedema)
- □ Non-invasive assessment of fibrosis:
- Serum biomarkers such as APRI (<1.0 means cirrhosis unlikely). Calculator available. hepatitisc.uw.edu/page/clinical-calculators/apri
- Elastography assessment e.g. FibroScan® (>12.5 kPa consistent with cirrhosis)
- Ultrasound assessment •

Check for other causes of liver disease

- □ Check for viral coinfection: 😣
- HIV Ab
- Hepatitis A check hep A IgG; vaccinate if negative
- Hepatitis B check HBsAg, anti-HBc and anti-HBs; vaccinate if all negative
- □ Heavy alcohol intake
- □ Fatty liver disease check weight, BMI

Check for other major co-morbidities

□ Renal impairment (eGFR < 50) 😣


Review previous HCV treatment

 Choice/length of treatment may be influenced by prior HCV treatment experience/response

Consider pregnancy and contraception

 HCV treatment not recommended for use in pregnant or lactating women

4 Treatment



- Check Egypt Guidelines for further information
- Check for drug-drug interactions at hep-druginteractions.org

~SOF/DAC = Sofosbuvir/Daclatasvir

Disclaimer: Guidance provided on this resource is based on best-practice at the time of publication. This quick-reference quide is not intended to be a comprehensive list of all available options.

Monitoring while on

5 Monitoring

- treatment Generally not required, but approach should be individualized
- Side effects of HCV treatment are generally minimal
- ٠ Consider monitoring adherence

12 weeks post 😣 treatment

- □ HCV RNA to confirm cure (sustained virological response SVR12 = cure)
- □ Liver enzymes

CONSULT WITH A SPECIALIST IF: **Pre-treatment**

During treatment

Post treatment

For more information:

Plan of Action for the Prevention, Care & Treatment of Viral Hepatitis, Egypt 2014 - 2018

6 Follow Up

If your patient has:

No cirrhosis and normal liver enzyme results (ALT< 45 IU/L) No clinical follow-up for HCV required

Ongoing risk factors

Annual HCV RNA test. If re-infected offer retreatment. Offer education on harm reduction strategies

Abnormal liver enzyme results

(ALT \geq 45 IU/L) Evaluate for other causes of liver disease and refer to specialist for review

Cirrhosis 🔝

Refer to specialist. Patients with cirrhosis require long-term monitoring:

 6-monthly abdominal ultrasound (hepatocellular carcinoma screening)

Consideration of screening for • esophageal varices

